Cirtec

Stories /
Healthcare /
Cirtec /

Nine acquisitions to date

Transformed from a North American specialist to a market-leading global medical device outsourcing platform

Investment date

2017 - Current

Good to great

>3x

revenue increase since investment

Transformed value proposition from component supplier to strategic outsourcing partner from design and development through vertically-integrated full device manufacture

Expanded therapeutic end-market exposure to several new high-growth end-markets including Structural Heart and Continuous Glucose Monitoring

9

acquisitions to date

Increased global employee base from c.400 to >1,600 and total footprint from c.141k to c.388k (square feet)

11

facilities across three jurisdictions

Executed on significant customer programme launches, supporting commercialisation of cutting-edge technologies

Key events under our ownership

Strategically accretive acquisitions of Precision Components, Vascotube, Metrigraphics, NovelCath, Cardea, Cactus and Top Tool, and certain high-value IP assets to broaden Cirtec’s capabilities and footprint offered to customers

Recruited William Hawkins (former Medtronic CEO) and William Ellerkamp (former ExtruMed CEO) to the Board of Directors

Completed three greenfield facility build-outs, adding >120 square feet of capacity and creating a low-cost footprint in Costa Rica

Executed four additional expansions of existing facilities to support customers with broader capacity

Supporting the company’s organic investments in capabilities and technology to more deeply vertically integrate within existing end-markets and expand capabilities to support entry into new markets

Opened a new 32,000 square-foot West Coast Center of Excellence in Santa Clara, California, dedicated to designing, developing, and manufacturing Class II and III cardiology and neurology devices